200 filings
8-K
EVFM
Evofem Biosciences, Inc.
27 Mar 24
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
8:36am
8-K
EVFM
Evofem Biosciences, Inc.
6 Mar 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EVFM
Evofem Biosciences, Inc.
1 Feb 24
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
9:05am
8-K
EVFM
Evofem Biosciences, Inc.
31 Jan 24
Entry into a Material Definitive Agreement
4:26pm
8-K/A
EVFM
Evofem Biosciences, Inc.
25 Jan 24
Financial Statements and Exhibits
4:23pm
8-K
b953rz5s
11 Jan 24
Entry into a Material Definitive Agreement
4:53pm
8-K
tc34yqmf yw6qjtf
26 Dec 23
Entry into a Material Definitive Agreement
5:37pm
8-K
umt9136x08g38t
12 Dec 23
Entry into a Material Definitive Agreement
5:17pm
8-K
zfmq20fe
7 Dec 23
Entry into a Material Definitive Agreement
4:05pm
8-K
g5x 819goa6uu2x
14 Nov 23
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
12:00am
8-K
lhctk6b 6bdhv6r4
24 Oct 23
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
7:40am
8-K
2ou85n6ibaxzemem
3 Oct 23
Entry into a Material Definitive Agreement
4:07pm
8-K
h4eqz ebu38x69kh
27 Sep 23
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem’s Phexxi Patents Expire
8:50am
8-K
5l2g67
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:49pm
8-K
fzqmr2ps51mo k6w
11 Sep 23
Entry into a Material Definitive Agreement
8:01am
8-K
v7my21cogvqpd5
28 Aug 23
Regulation FD Disclosure
4:30pm
8-K/A
4knfxaz8ys
18 Aug 23
Entry into a Material Definitive Agreement
4:05pm
8-K
d3mk gyar
14 Aug 23
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
5:25pm
8-K
amjed 16t3tkcpghdif
10 Aug 23
Entry into a Material Definitive Agreement
5:29pm
8-K
ikzul1mou kx9knjw
17 Jul 23
Material Modifications to Rights of Security Holders
4:05pm